

# Quality Council

## December 16, 2021



---

# Agenda

<u>Time</u>	<u>Topic</u>
4:00 p.m.	Call to Order
4:05 p.m.	Public Comment
4:15 p.m.	Approval of November 18, 2021 Meeting Minutes
4:20 pm	Vote on 2022 Meeting Schedule
4:25 p.m.	Follow-up from the November 18, 2021 Meeting
4:55 p.m.	Break
5:00 p.m.	Discuss Medicare Advantage Quality Benchmark Values
5:30 p.m.	2021 Reflections
5:55 p.m.	Wrap-up & Next Steps
6:00 p.m.	Adjourn

# Call to Order

# Public Comment

# Approval of November 18, 2021 Meeting Minutes

# Vote on 2022 Meeting Schedule

# Follow-up from the November 18, 2021 Meeting

# Quality Benchmark Measures

- During the last meeting, the Quality Council indicated that it recommended retaining *Asthma Medication Ratio* despite flaws associated with the measure.
  - OHS will retain the measure in the Phase 1 Quality Benchmarks.
  - OHS recommends setting different Benchmark values for the pediatric and adult populations.



# Asthma Medication Ratio – Ages 5-18

Description	Steward	Measure Type	Data Source	Population
Percentage of members 5–64 who were identified as having persistent asthma and had a ratio of controller medications to total asthma medications of 0.50 or greater	NCQA	Process	Claims	Adult and Pediatric

- CT performance

2019	79
2018	79
2017	81

**A higher rate indicates better performance**

- Nat'l commercial performance (2019)

Nat'l 25 <sup>th</sup>	81
Nat'l 50 <sup>th</sup>	84
Nat'l 75 <sup>th</sup>	88
Nat'l 90 <sup>th</sup>	90

CT performance is a weighted average of four commercial plans' performance.  
 Nat'l: National

# Asthma Medication Ratio – Ages 19-64

Description	Steward	Measure Type	Data Source	Population
Percentage of members 5–64 who were identified as having persistent asthma and had a ratio of controller medications to total asthma medications of 0.50 or greater	NCQA	Process	Claims	Adult and Pediatric

- CT performance

2019	78
2018	81
2017	79

**A higher rate indicates better performance**

- Nat'l commercial performance (2019)

Nat'l 25 <sup>th</sup>	74
Nat'l 50 <sup>th</sup>	79
Nat'l 75 <sup>th</sup>	82
Nat'l 90 <sup>th</sup>	85

CT performance is a weighted average of four commercial plans' performance.  
 Nat'l: National

# Asthma Medication Ratio – Ages 5-18

Description	Steward	Measure Type	Data Source	Population
Percentage of members 5–64 who were identified as having persistent asthma and had a ratio of controller medications to total asthma medications of 0.50 or greater	NCQA	Process	Claims	Adult and Pediatric

- CT performance

2019	66
2018	66
2017	70

**A higher rate indicates better performance**

- Nat'l Medicaid performance (2019)

Nat'l 25 <sup>th</sup>	65
Nat'l 50 <sup>th</sup>	70
Nat'l 75 <sup>th</sup>	75
Nat'l 90 <sup>th</sup>	80

CT DSS performance is a weighted average of HUSKY A/B, C and D performance.  
 Nat'l: National

# Asthma Medication Ratio – Ages 19-64

Description	Steward	Measure Type	Data Source	Population
Percentage of members 5–64 who were identified as having persistent asthma and had a ratio of controller medications to total asthma medications of 0.50 or greater	NCQA	Process	Claims	Adult and Pediatric

- CT performance

2019	63
2018	65
2017	70

**A higher rate indicates better performance**

- NE Medicaid performance (2019)

Nat'l 25 <sup>th</sup>	51
Nat'l 50 <sup>th</sup>	56
Nat'l 75 <sup>th</sup>	63
Nat'l 90 <sup>th</sup>	83

CT DSS performance is a weighted average of HUSKY A/B, C and D performance.  
NE: New England

# Quality Benchmark Measures (Cont'd)

- The Council also received feedback recommending inclusion of a drug overdose measure.
  - While OHS agrees that drug overdose is an important health policy topic, it will not include any measures focused on drug overdoses in the Quality Benchmarks because:
    - OHS is prioritizing measures that can be applied at the **AN level** and
    - OHS aims to create alignment between the Quality Benchmarks and the **Core Measure Set**, and there are no drug overdose-focused measures in the Core Measure Set.
- The Council, however, can consider drug overdose measures during the 2022 annual review of the Core Measure Set.

# Quality Benchmark Measures (Cont'd)

- Revised Quality Benchmarks (if OHS adopts the recommendations on the previous slide):

## Phase 1: Beginning for 2022

- Asthma Medication Ratio
- Controlling High Blood Pressure
- Hemoglobin A1c (HbA1c) Control for Patients with Diabetes: HbA1c Poor Control

## Phase 2: Beginning for 2024

- Child and Adolescent Well-Care Visits
- Follow-up After Hospitalization for Mental Illness (7-day)
- Follow-up After ED Visit for Mental Illness (7-day)
- Obesity Equity Measure

# Summary of Benchmark Value Recommendations

- The Quality Council reviewed and recommended Quality Benchmark values for the commercial and Medicaid market.
  - The Council recommended a 2025 Benchmark value for each measure based on performance in 2019.
    - OHS is adopting the Council's recommendation to set the 2022 Benchmark value at the 2019 baseline rate for all measures for all markets.
  - The Council had mixed feedback on how to set Benchmark values for 2023 and 2024. OHS is proposing to set targets for 2023 and 2024 for that reflect equal annual performance improvement.

# Commercial Market Phase 1 Quality Benchmark Values

- OHS is adopting the Quality Council’s recommended Benchmark values for Phase 1 measures for the commercial market.

Quality Benchmark Measure	2022 Value	2023 Value	2024 Value	2025 Value	Reference Source
Asthma Medication Ratio (Ages 5-18)	Discussed earlier in the meeting				
Asthma Medication Ratio (Ages 19-64)	Discussed earlier in the meeting				
Controlling High Blood Pressure	61%	63%	65%	68%	Between the New England commercial 50 <sup>th</sup> and 75 <sup>th</sup>
HbA1c Control for Patients with Diabetes: HbA1c >9%*	27%	26%	25%	23%	Between the national commercial 75 <sup>th</sup> and 90 <sup>th</sup>

The differences between Benchmark values may not be equal due to rounding.

\*A lower rate indicates higher performance.



# Commercial Market Phase 2 Quality Benchmark Values

- OHS is adopting the Quality Council’s recommended Benchmark values for Phase 2 measures for the commercial market.

Quality Benchmark Measure	2025 Value	Reference Source
Child and Adolescent Well-Care Visits	TBD	TBD – will be set in winter / spring 2023
Follow-up After ED Visit for Mental Illness (7-Day)	71%	New England commercial 75 <sup>th</sup> percentile
Follow-up After Hospitalization for Mental Illness (7-Day)	65%	New England commercial 90 <sup>th</sup> percentile

The differences between Benchmark values may not be equal due to rounding.

# Medicaid Market Phase 1 Quality Benchmark Values

- The DSS Transparency Council is reviewing the Quality Council's recommended Benchmark values for the Medicaid market on December 17<sup>th</sup>.

Quality Benchmark Measure	2022 Value	2023 Value	2024 Value	2025 Value	Reference Source
Asthma Medication Ratio (Ages 5-18)	Discussed earlier in the meeting				
Asthma Medication Ratio (Ages 19-64)	Discussed earlier in the meeting				
Controlling High Blood Pressure	61%	63%	65%	68%	National Medicaid 75 <sup>th</sup> percentile
HbA1c Control for Patients with Diabetes: HbA1c >9%*	37%	36%	35%	33%	National Medicaid 75 <sup>th</sup> percentile

The differences between Benchmark values may not be equal due to rounding.

\*A lower rate indicates higher performance.

# Medicaid Market Phase 2 Quality Benchmark Values

- The DSS Transparency Council is reviewing the Quality Council's recommended Benchmark values for the Medicaid market on December 17<sup>th</sup>.

Quality Benchmark Measure	2025 Value	Reference Source
Child and Adolescent Well-Care Visits	TBD	TBD – will be set in winter / spring 2023
Follow-up After ED Visit for Mental Illness (7-Day)	65%	National Medicaid 90 <sup>th</sup> percentile
Follow-up After Hospitalization for Mental Illness (7-Day)	55%	New England Medicaid 90 <sup>th</sup> percentile

The differences between Benchmark values may not be equal due to rounding.

# Recommended Statewide Market Benchmark Values

- OHS is adopting the Quality Council’s recommended Benchmark values for the *Obesity Equity Measure*.

Quality Benchmark Measure	2022 Value	2023 Value	2024 Value	2025 Value	Reference Source
Obesity Equity Measure <i>the difference in the obesity rates of the White, non-Hispanic and Black, non-Hispanic race/ethnicity populations</i>	17	15	13	10	2019 Behavioral Risk Factor Surveillance System

The differences between Benchmark values may not be equal due to rounding.

# Discuss Medicare Advantage Quality Benchmark Values

# Medicare Advantage Quality Benchmark Values

- The Quality Council will now recommend Quality Benchmark values for the Medicare Advantage market.
- As a reminder, OHS is proposing to set Benchmark values for only two measures that it believes insurance carriers are using in their Medicare Advantage contracts:
  - Controlling High Blood Pressure
  - Hemoglobin A1c (HbA1c) Control: HbA1c Poor Control (>9.0%)

# Controlling High Blood Pressure

Description	Steward	Measure Type	Data Source	Population
Percentage of members 18–85 years of age who had a diagnosis of hypertension (HTN) and whose blood pressure was adequately controlled (<140/90 mm Hg)	NCQA	Outcome	Claims and Clinical Data	Adult

- CT average performance

2018	73
------	----

**A higher rate indicates better performance**

- Nat'l Medicare performance (2018)

Nat'l 25 <sup>th</sup>	63
Nat'l 50 <sup>th</sup>	74
Nat'l 75 <sup>th</sup>	80
Nat'l 90 <sup>h</sup>	86

NCQA could only provide an average CT and national rate for 2018.

Nat'l: National

# Hemoglobin A1c (HbA1c) Control for Patients with Diabetes: HbA1c Poor Control (>9.0%)

Description	Steward	Measure Type	Data Source	Population
Percentage of members 18–75 years of age with diabetes (types 1 and 2) whose hemoglobin A1c (HbA1c) was >9.0%	NCQA	Outcome	Claims and Clinical Data	Adult

- CT average performance

2018	20
------	----

**A lower rate indicates better performance**

- Nat'l Medicare performance (2018)

Nat'l 25 <sup>th</sup>	28
Nat'l 50 <sup>th</sup>	20
Nat'l 75 <sup>th</sup>	15
Nat'l 90 <sup>h</sup>	12

NCQA could only provide an average CT and national rate for 2018.

Nat'l: National



# 2021 Reflections

# 2021 Reflections

- Thank you for a productive and engaging year of Quality Council meetings!
- As we reflect on our shared work over the past year, do you have any:
  - lessons learned from the 2021 meeting series and/or
  - hopes / feedback for our work in 2022?

# Wrap-up & Next Steps

# Meeting Wrap-Up & Next Steps

- OHS is drafting a report that summarizes the Quality Council's recommendations on the Quality Benchmark measures and values.
  - It will solicit feedback on the draft report for the Quality Council's feedback in January 2022.
- When we regroup in 2022, the Quality Council will:
  - discuss any outstanding items related to the Quality Benchmarks,
  - discuss strategies to generate action on the Quality Benchmarks, and
  - commence a 2022 annual review of the Core Measure Set.

